![]() |
Name |
Cytoglobosin E
|
Molecular Formula | C32H36N2O5 | |
IUPAC Name* |
(1S,7E,9S,11E,13S,16S,17R,18S)-15-(hydroxymethyl)-18-(1H-indol-3-ylmethyl)-7,9,16-trimethyl-19-azatricyclo[11.7.0.01,17]icosa-7,11,14-triene-2,5,6,20-tetrone
|
|
SMILES |
C[C@H]\1C/C=C/[C@H]2C=C([C@H]([C@@H]3[C@@]2(C(=O)CCC(=O)C(=O)/C(=C1)/C)C(=O)N[C@H]3CC4=CNC5=CC=CC=C54)C)CO
|
|
InChI |
InChI=1S/C32H36N2O5/c1-18-7-6-8-23-14-22(17-35)20(3)29-26(15-21-16-33-25-10-5-4-9-24(21)25)34-31(39)32(23,29)28(37)12-11-27(36)30(38)19(2)13-18/h4-6,8-10,13-14,16,18,20,23,26,29,33,35H,7,11-12,15,17H2,1-3H3,(H,34,39)/b8-6+,19-13+/t18-,20+,23-,26-,29-,32+/m0/s1
|
|
InChIKey |
HBNDUJJOOQPFON-VTIMCAMGSA-N
|
|
Synonyms |
Cytoglobosin E; CHEBI:68763; CHEMBL1097909; Q27137166; (3S,3aR,4S,6aS,7E,10S,11E,17aS)-5-(hydroxymethyl)-3-(1H-indol-3-ylmethyl)-4,10,12-trimethyl-3,3a,4,6a,9,10,15,16-octahydro-1H-cyclotrideca[d]isoindole-1,13,14,17(2H)-tetrone
|
|
CAS | NA | |
PubChem CID | 46209920 | |
ChEMBL ID | CHEMBL1097909 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 528.6 | ALogp: | 3.1 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 116.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 39 | QED Weighted: | 0.305 |
Caco-2 Permeability: | -4.911 | MDCK Permeability: | 0.00001100 |
Pgp-inhibitor: | 0.136 | Pgp-substrate: | 0.992 |
Human Intestinal Absorption (HIA): | 0.085 | 20% Bioavailability (F20%): | 0.538 |
30% Bioavailability (F30%): | 0.006 |
Blood-Brain-Barrier Penetration (BBB): | 0.795 | Plasma Protein Binding (PPB): | 97.23% |
Volume Distribution (VD): | 0.464 | Fu: | 2.04% |
CYP1A2-inhibitor: | 0.15 | CYP1A2-substrate: | 0.192 |
CYP2C19-inhibitor: | 0.516 | CYP2C19-substrate: | 0.277 |
CYP2C9-inhibitor: | 0.545 | CYP2C9-substrate: | 0.243 |
CYP2D6-inhibitor: | 0.254 | CYP2D6-substrate: | 0.158 |
CYP3A4-inhibitor: | 0.955 | CYP3A4-substrate: | 0.25 |
Clearance (CL): | 7.062 | Half-life (T1/2): | 0.347 |
hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.195 |
Drug-inuced Liver Injury (DILI): | 0.901 | AMES Toxicity: | 0.505 |
Rat Oral Acute Toxicity: | 0.908 | Maximum Recommended Daily Dose: | 0.958 |
Skin Sensitization: | 0.423 | Carcinogencity: | 0.754 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
Respiratory Toxicity: | 0.985 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002442 | ![]() |
0.779 | D02DMQ | ![]() |
0.272 | ||
ENC003245 | ![]() |
0.720 | D09ZIO | ![]() |
0.264 | ||
ENC003856 | ![]() |
0.718 | D01TSI | ![]() |
0.261 | ||
ENC004465 | ![]() |
0.717 | D0V3ZA | ![]() |
0.254 | ||
ENC002441 | ![]() |
0.709 | D09NNH | ![]() |
0.254 | ||
ENC005215 | ![]() |
0.654 | D0SP3D | ![]() |
0.254 | ||
ENC004447 | ![]() |
0.632 | D02XIY | ![]() |
0.247 | ||
ENC002681 | ![]() |
0.632 | D0W7WC | ![]() |
0.247 | ||
ENC002151 | ![]() |
0.602 | D0BV3J | ![]() |
0.246 | ||
ENC003586 | ![]() |
0.591 | D0X9PF | ![]() |
0.238 |